Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg TR-701 Free Acid in Healthy Volunteers

The primary purpose of this study is to determine the steady-state plasma pharmacokinetics (PK) and properties of TR-700 into the pulmonary epithelial lining fluid (ELF) and alveolar macrophages (AM) of healthy volunteers.

No applicable.

Inclusion Criteria:

• Healthy males and females, between 18 and 55 years of age, inclusive
• Females must be nonpregnant, nonlactating, and either postmenopausal or surgically sterile or practicing an effective method of birth control
• Males must be surgically sterile, abstinent, or practicing an effective method of birth control
• BMI between 20 and 34.9 kg/m2, inclusive

Exclusion Criteria:

• Allergy to lidocaine, midazolam, or other anesthetics/sedatives of similar classes
• Physician-diagnosed migraine headaches within 3 years
• Previous enrollment in a TR-701 or TR-701 FA trial